Stroke Prevention and Management

Risk Factors and Patient Profile

Previous stroke is a major risk factor for recurrent stroke, placing patients in a high-risk category requiring anticoagulation, according to the American Heart Association 1
Patients with severe left ventricular dysfunction (reduced ejection fraction) or heart failure have a higher risk of thromboembolism, including stroke, as stated by the American College of Cardiology and the American Heart Association 2

Consider left atrial appendage closure in patients who have contraindications for lifelong anticoagulation, as recommended by the American Stroke Association 1
The American Heart Association recommends apixaban over warfarin for patients with stroke and atrial fibrillation due to its superior safety profile with lower bleeding risks while maintaining effective stroke prevention 1
For patients at high risk of hemorrhagic conversion, delaying initiation of anticoagulation beyond 14 days is reasonable, and the American College of Chest Physicians recommends starting oral anticoagulation within 2 weeks of acute ischemic stroke in patients with atrial fibrillation, with specific timing based on stroke severity:
Stroke Severity Recommended Timing
TIA 1 day (immediate)
Mild stroke >3 days post-stroke
Moderate stroke >6-8 days post-stroke
Severe stroke >12-14 days post-stroke
3, 4
Brain imaging should be repeated before initiating anticoagulation in moderate to severe strokes to exclude hemorrhagic transformation, as recommended by the European Heart Society 4
Very early anticoagulation (within 48 hours) using heparinoids or VKAs should be avoided, as it increases the risk of symptomatic intracranial hemorrhage without providing net benefit, while early (<14 days) anticoagulation with NOACs might be safe 3

Apixaban is recommended as a first-line anticoagulant for preventing recurrent stroke in patients with a history of embolic stroke due to atrial fibrillation, offering superior safety and comparable efficacy to warfarin, with a standard dosing of 5 mg twice daily, and dose reduction to 2.5 mg twice daily if the patient has at least two of the following characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 1
Warfarin (target INR 2.0-3.0) is recommended as second-line therapy for patients who cannot take DOACs, requiring regular INR monitoring 1, 5, 2
For patients on DOACs, monitor renal function at least annually, more frequently if impaired, and assess medication adherence at each follow-up visit, as medication adherence is crucial for DOAC effectiveness due to their short half-lives 2

Apixaban should NOT be used in patients with moderate to severe mitral stenosis or mechanical heart valves, due to increased risk of adverse events, and is contraindicated in patients with a history of hemorrhagic stroke due to increased risk of recurrent intracerebral hemorrhage 1, 6
Dabigatran is contraindicated in patients with severe renal impairment (creatinine clearance ≤30 mL/min), and for patients with end-stage renal disease or on dialysis, warfarin or dose-adjusted apixaban may be reasonable 7, 1
Avoid combining anticoagulants with antiplatelets unless specifically indicated, as this significantly increases bleeding risk 8

Apixaban has demonstrated significant benefits in preventing recurrent strokes in patients with atrial fibrillation, with a reduction in stroke and systemic embolism of 1.27% versus 1.60% per year compared to warfarin, and reduced all-cause mortality by 11% compared to warfarin, with a strength of evidence based on the ARISTOTLE trial 1, 9
Apixaban reduced major bleeding risk by 31% compared to warfarin, with a rate of 2.13% versus 3.09% per year, and reduced hemorrhagic stroke risk by 49% compared to warfarin, highlighting its superior safety profile 1, 9